Biotech and Pharmaceuticals Pharmaceuticals

  • U.S. stock index futures inched higher ahead of a crucial report on nonfarm payrolls Friday, while stocks abroad also climbed.

  • Stocks eked out a modest gain Thursday after some encouraging economic news ahead of tomorrow's jobs report. Consumer stocks were the day's top performers after upgrades on Disney and Coke and better-than-expected retail-sales reports.

  • This morning, BMO Capital Markets biotech analyst Jason Zhang downgraded shares of Amylin Pharmaceuticals to the equivalent of "Sell."

  • Stocks pulled back Thursday after a report showed an unexpected drop in pending-home sales. Stocks had opened higher Thursday after a report showed jobless claims fell last week and retail sales came in better than expected.

  • Stocks pulled back Thursday after a report showed an unexpected drop in pending-home sales. Stocks had opened higher Thursday after a report showed jobless claims fell last week and retail sales came in better than expected.

  • Wall Street is in an unusually extended "wait-and-see" mode, as evidenced by the recent lack of movement in the major averages and little change Thursday in stock index futures.

  • President Barack Obama

    President Obama has high cholesterol. For now, his doctors are prescribing healthy living. But some say he should be put on a statin or cholesterol-lowering drug pronto.

  • Shares of Dendreon fell around 10 percent before the market opened. And now, in regular trading, they're at a new intra-day high. Here's what happened.

  • tv_interview_200.jpg

    When a major pharma company holds analyst/investor meetings as infrequently as Bristol-Myers Squibb, it's kind of a must-cover event.

  • President Obama talked through the issues of health care reform on Thursday in a bipartisan summit. The unprecedented event comes as the president tries to get his reform plans back on track. Charles Boorady, health care providers analyst at Citigroup, discussed the summit and shared his investment strategies. 

  • A snowy Capitol Hill in Washington, DC.

    The Food and Drug Administration says its decisions are always based on the science. But on rare occasions ol' mother nature apparently can get in the way.

  • The company logo of GlaxoSmithKline, is seen on the headquarters building in London, Wednesday May 10, 2006. GlaxoSmithKline PLC said Wednesday it has been granted a High Court injunction against animal rights activists who sent threats to the drugmaker's shareholders, barring them from sending more letters or revealing private information about the investors. (AP Photo/Alastair Grant)

    On day five of Avandiagate, GlaxoSmithKline communiques about the brouhaha surrounding the controversial diabetes drug now number six.

  • A correction is “clearly on its way” since the start of the year, but investors can still make money in this market environment, said Enzio von Pfeil, CEO of EconomicClock.com. He shared his market strategies.

  • The company is suing more than half a dozen generic drug firms that want to make a cheaper copy of Crestor years before the patent on the drug is set to expire. But you won't find me sitting in the pews furiously taking notes.

  • I suppose it’s possible President Obama could have come up with a more anti-market reform to deal with its concerns over higher health insurance rates, but short of creating a single-payer health system, creating a seven-member panel to dictate the prices of health insurance is pretty close.

  • Cost of healthcare

    Big pharmaceutical companies have been raising prices on a lot of drugs recently. Some critics say the industry's trying to cash in before government price controls possibly get put into place.

  • Toyota headquarters

    As someone who studies the way people perceive risk, and the importance of trust to those perceptions, it continues to amaze me how many smart successful firms like Toyota manage to forget the importance of trust until they’re in trouble, and then they have to spend huge amounts of money and effort, for years, trying to rebuild it, writes the author David Ropeik.

  • The stock market, being that discounting mechanism that it is, is not going to take this lightly, but instead treat this as a starting pistol to a difficult period of the removal of easy money for the markets, culminating in a hike of the Fed Funds rate.

  • Former U.S. President Bill Clinton seen speaking during the inaugural Rural Summit in Washington, DC

    A source tells CNBC that former President Bill Clinton received two drug-coated stents, called "Xience," made by Abbott Labs.

  • Healthcare coverage and the hastle of forms

    Washington’s new political reality has left the fate of comprehensive healthcare reform uncertain, but there’s still plenty Congress and the Obama administration can do to improve the American healthcare system, writes this CEO.